Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of October 3, 2026, ABT trades at $97.40 with a market cap of $167.31B and a P/E ratio of 31.37. ABT moved +0.85% today. Year to date, ABT is -21.49%; over the trailing twelve months it is -26.69%. Its 52-week range spans $81.97 to $141.23. Analyst consensus is strong buy with an average price target of $124.33. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Abbott to release Q3 2026 results, host earnings call: Abbott will release third-quarter 2026 results on Oct. 21 before the market opens and host a live earnings call webcast at 8 a.m. CT (9 a.m. ET).
| Metric | Value |
|---|---|
| Price | $97.40 |
| Market Cap | $167.31B |
| P/E Ratio | 31.37 |
| EPS | $3.10 |
| Dividend Yield | 0.63% |
| 52-Week High | $141.23 |
| 52-Week Low | $81.97 |
| Volume | 6.57M |
| Avg Volume | 0 |
| Revenue (TTM) | $46.59B |
| Net Income | $5.42B |
| Gross Margin | 56.61% |
15 analysts cover ABT: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $124.33.